Literature DB >> 24601644

Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

Ana Z Gonzalez1, Zhihong Li, Hilary P Beck, Jude Canon, Ada Chen, David Chow, Jason Duquette, John Eksterowicz, Brian M Fox, Jiasheng Fu, Xin Huang, Jonathan Houze, Lixia Jin, Yihong Li, Yun Ling, Mei-Chu Lo, Alexander M Long, Lawrence R McGee, Joel McIntosh, Jonathan D Oliner, Tao Osgood, Yosup Rew, Anne Y Saiki, Paul Shaffer, Sarah Wortman, Peter Yakowec, Xuelei Yan, Qiuping Ye, Dongyin Yu, Xiaoning Zhao, Jing Zhou, Steven H Olson, Daqing Sun, Julio C Medina.   

Abstract

We previously reported the discovery of potent and selective morpholinone and piperidinone inhibitors of the MDM2-p53 interaction. These inhibitors have in common a carboxylic acid moiety that engages in an electrostatic interaction with MDM2-His96. Our continued search for potent and diverse inhibitors led to the discovery of novel replacements for these acids uncovering new interactions with the MDM2 protein. In particular, using pyridine or thiazole as isosteres of the carboxylic acid moiety resulted in very potent analogues. From these, AM-6761 (4) emerged as a potent inhibitor with remarkable biochemical (HTRF IC50 = 0.1 nM) and cellular potency (SJSA-1 EdU IC50 = 16 nM), as well as favorable pharmacokinetic properties. Compound 4 also shows excellent antitumor activity in the SJSA-1 osteosarcoma xenograft model with an ED50 of 11 mg/kg. Optimization efforts toward the discovery of these inhibitors as well as the new interactions observed with the MDM2 protein are described herein.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24601644     DOI: 10.1021/jm401911v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Hydrogen Bonding of 1,2-Azaborines in the Binding Cavity of T4 Lysozyme Mutants: Structures and Thermodynamics.

Authors:  Hyelee Lee; Marcus Fischer; Brian K Shoichet; Shih-Yuan Liu
Journal:  J Am Chem Soc       Date:  2016-09-12       Impact factor: 15.419

Review 2.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

Review 3.  Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:  Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou
Journal:  J Hematol Oncol       Date:  2022-07-13       Impact factor: 23.168

Review 4.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

Review 5.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

Review 6.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.